You are here:

Iloprost trometamol nebuliser solution (Ventavis®)

Advice

Following a full submission

Iloprost trometamol nebuliser solution (Ventavis®) is accepted for restricted use within NHS Scotland for the treatment of patients with New York Heart Association Class III primary pulmonary hypertension as a second-line treatment where bosentan is ineffective or is not tolerated. It is an orphan product and efficacy data are very limited.

Iloprost should also be restricted to use only as an alternative in patients receiving other forms of prostacyclin treatment. It is not recommended for patients who would not otherwise have received prostacyclin treatment because it is not cost effective in this situation.

It is further restricted only to use by Specialists working in the Scottish Pulmonary Vascular Unit.

Drug Details

Drug Name: Iloprost trometamol nebuliser solution (Ventavis®)
SMC Drug ID: 219/05
Manufacturer: Schering Health Care Ltd
Indication: Primary pulmonary hypertension
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Full submission
Status: Restricted
Date Advice Published: 12 December 2005

Back